Experimental Construction of BMP2 and VEGF Gene Modified Tissue Engineering Bone in Vitro

International Journal of Molecular Sciences

Jia Jiang¹  Cun-Yi Fan² 

[1]Department of Sports Medicine and Arthroscopic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China

[2] E-Mail:

[3]Department of Orthopedics, The Sixth Affiliated People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China

[4] E-Mail:

关键词: bone morphogenetic protein 2;    co-transfection;    lentiviral vector;    tissue engineering bone;    vascular endothelial growth factor;    β-tricalcium phosphate (β-TCP);   

DOI  :  10.3390/ijms12031744

来源: mdpi

【 摘 要 】

The purpose of this study was to investigate the feasibility and advantages of constructing a novel tissue engineering bone, using β-tricalcium phosphate (β-TCP) and rat bone marrow mesenchymal stem cells (MSCs), modified with human bone morphogenetic protein 2 gene (hBMP2) and human vascular endothelial growth factor 165 gene (hVEGF165), through lentiviral transfection. Both genes were successfully co-expressed in the co-transfection group for up to eight weeks confirmed by enzyme-linked immunosorbent assay (ELISA). After seeding MSCs onto the scaffolds, scanning electron microscopy (SEM) observation showed that MSCs grew and proliferated well in co-transfection group at 7 and 14 days. There was no significant difference among all the groups in hoechst DNA assay for cell proliferation for 14 days after cell seeding (P > 0.05), but the highest alkaline phosphatase (ALP) activity was observed in the co-transfection group at 14 days after cell seeding (p < 0.01). These results demonstrated that it was advantageous to construct tissue engineering bone using β-TCP combined with MSCs lentivirally co-transfected with BMP2 and VEGF165, providing an innovative way for treating bone defects.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.